Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610393 | 0.98 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL3098117 | 0.98 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8838781 | 0.92 | ALDH1A1 (0.54) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL4609866 | 0.90 | ALDH1A1 (0.46) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8886404 | 0.90 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8883429 | 0.88 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL1110043 | 0.88 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL4608593 | 0.88 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8885551 | 0.88 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL1110056 | 0.88 | LMNA (0.50) | ALDH1A1TDP1LMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105985774-B | The application of nanocrystalline-ligand complex, preparation method, printing material and printing material | 纳晶科技股份有限公司 | 2019-05-28 | — | — | CN | claimed |
| CN-105985774-A | Nanocrystalline-ligand compound, preparation method of nanocrystalline-ligand compound, printing material and use of printing material | 纳晶科技股份有限公司 | 2016-10-05 | — | — | CN | claimed |
| CN-105985774-B | The application of nanocrystalline-ligand complex, preparation method, printing material and printing material | 纳晶科技股份有限公司 | 2019-05-28 | — | — | CN | disclosed |
| CN-105985774-A | Nanocrystalline-ligand compound, preparation method of nanocrystalline-ligand compound, printing material and use of printing material | 纳晶科技股份有限公司 | 2016-10-05 | — | — | CN | disclosed |
| EP-2280009-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND FUNGICIDES FOR AGRICULTURAL AND HORTICULTURAL USE | Nippon Soda Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | ALDH1A1 356/4885TDP1 4351/4885LMNA 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.